Combining the analysis of IL-22 expression levels with clinical data, we found that patients with high IL-22 expression presented with larger tumor diameters, more frequent microvascular invasion, and were more likely to be at an advanced stage of the disease (Stage III) at diagnosis (Table 1). This evidence concerns the gene IL22 and neoplasm.